From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
The absolute neutrophil count (ANC) of 1180 cells/mm³ is within the low-normal range, and according to the most recent study 1, no immediate intervention is required, but monitoring with repeat complete blood counts would be appropriate to ensure stability. This value is above the threshold for neutropenia, which is typically defined as an ANC below 1000 cells/mm³. However, this count is on the lower end of normal, which typically ranges from 1500-8000 cells/mm³. Some key points to consider:
- Causes of a borderline low neutrophil count can include viral infections, certain medications, autoimmune disorders, or normal variation in some individuals.
- If the patient is experiencing recurrent infections, fever, or has other concerning symptoms, further evaluation by a healthcare provider would be warranted.
- The neutrophil count is important because these white blood cells are crucial for fighting bacterial infections, and significantly lower levels could increase infection risk.
- A study on granulocyte colony-stimulating factor (G-CSF) use in patients with chemotherapy-induced neutropenia found that G-CSF can reduce the rates of febrile neutropenia and febrile neutropenia-related hospitalization 2.
- Another study on the mechanism of G-CSF that induces the mobilization of neutrophils found that understanding the G-CSF structure, expression, mechanism of action, and how it induces neutrophils mobilization is crucial to producing promising cancer therapy 3. However, the most recent and highest quality study 1 suggests that the use of G-CSF in patients with severe chronic neutropenia can lead to improved outcomes, but the decision to use G-CSF should be made on a case-by-case basis, taking into account the individual patient's underlying condition and medical history.